Amgen (AMGN)
(Delayed Data from NSDQ)
$272.45 USD
+2.81 (1.04%)
Updated Dec 1, 2023 04:00 PM ET
After-Market: $272.40 -0.05 (-0.02%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
Amgen (AMGN) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$279.33 | $336.00 | $185.00 | 3.59% |
Price Target
Based on short-term price targets offered by 18 analysts, the average price target for Amgen comes to $279.33. The forecasts range from a low of $185.00 to a high of $336.00. The average price target represents an increase of 3.59% from the last closing price of $269.64.
Analyst Price Targets (18)
Broker Rating
Amgen currently has an average brokerage recommendation (ABR) of 2.36 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 22 brokerage firms. The current ABR compares to an ABR of 2.33 a month ago based on 21 recommendations.
Of the 22 recommendations deriving the current ABR, nine are Strong Buy, representing 40.91% of all recommendations. A month ago, Strong Buy represented 42.86%.
Broker Rating Breakdown

Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 9 | 9 | 9 | 7 | 7 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 11 | 11 | 10 | 8 | 8 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 2 | 2 | 2 | 2 | 2 |
ABR | 2.36 | 2.36 | 2.33 | 2.41 | 2.41 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
11/29/2023 | Truist Securities | Robyn Karnauskas | Strong Buy | Strong Buy |
11/3/2023 | William Blair | Matt Phipps | Hold | Hold |
10/17/2023 | Argus Research Corp. | David A Toung | Strong Buy | Strong Buy |
10/11/2023 | SVB Securities | David Risinger | Hold | Strong Buy |
8/14/2023 | Mizuho SecuritiesUSA | Salim Syed | Hold | Hold |
8/4/2023 | Piper Sandler | Christopher Raymond | Strong Buy | Strong Buy |
8/3/2023 | Not Identified | Not Identified | Hold | Hold |
8/3/2023 | Not Identified | Not Identified | Hold | Hold |
8/2/2023 | Atlantic Equities | Steven K Chesney | Strong Sell | Strong Sell |
2/1/2023 | BMO Capital Markets | Evan Seigerman | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.36 |
ABR (Last week) | 2.36 |
# of Recs in ABR | 22 |
Average Target Price | $279.33 |
LT Growth Rate | 5.60% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 47 of 252 |
Current Quarter EPS Est: | 4.67 |